• Molecule Holdings (MLCL) has entered into a sales amendment partnership with Great White North Growers
  • The agreement will see Molecule sell cannabis in the Québec market via the Société Québécoise du cannabis
  • The Société is Québec’s exclusive wholesale and retail distributor for the province
  • Molecule’s goal is to be the on-ramp for companies wishing to enter into the cannabis beverage and edibles market, but choose not to go through the process of obtaining required cannabis licences
  • Molecule Holdings is unchanged, trading at $0.11 at 1:11 pm ET

Molecule Holdings (MLCL) has entered into a sales amendment partnership with Great White North Growers.

The agreement will see Molecule sell cannabis in the Québec market via the Société Québécoise du cannabis.
The Société is Québec’s exclusive wholesale and retail distributor for the province.
Molecule works with client-partners to engage in the production of cannabis-infused beverages and edibles. The company provides the infrastructure, know-how, technology, and licensing for craft producers to create consumable cannabis products. Molecule’s goal is to be the on-ramp for companies wishing to enter into the cannabis beverage and edibles market, but who choose not to go through the significant process of obtaining the required cannabis licences.
Great White North Growing is a privately held producer of premium pharmaceutical-grade medical and recreational cannabis, based out of the Ville d’Anjou, a borough of the island of Montreal.
“We are excited to enter the Québec market. We feel our unique family of beverages together with GWNG’s experience and highly Québec-centric focus is a winning combination. Entering Québec is the first step in our national expansion, expecting to now pick-up speed since launching in Ontario in April,” said Molecule President and CEO, Phil Waddington.
Molecule Holdings is unchanged, trading at $0.11 at 1:11 pm ET.
More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.